Percutaneous tricuspid valve repair: A safer alternative to traditional approaches?
- 15 December 2022
- journal article
- editorial
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 100 (7) , 1300-1301
Abstract
Key Points: The use of the PASCAL transcatheter valve repair system is a safe and feasible approach for treating patients with severe, symptomatic tricuspid regurgitation and is associated with improved quality‐of‐life outcomes at 30 days. The TriCLASP study adds to the growing body of evidence supporting the use of transcatheter tricuspid valve interventions for treating severe tricuspid regurgitation in high‐risk surgical patients. In the highly anticipated CLASP II TR pivotal trial (NCT04097145), patients will be randomized to receive treatment with the PASCAL system and optimal medical therapy or optimal medical therapy alone.Keywords
This publication has 4 references indexed in Scilit:
- Transcatheter valve repair of tricuspid regurgitation with the PASCAL system: TriCLASP study 30‐day resultsCatheterization and Cardiovascular Interventions, 2022
- Feasibility Study of the Transcatheter Valve Repair System for Severe Tricuspid RegurgitationJACC, 2021
- Transcatheter Edge-to-Edge Repair for Treatment of Tricuspid RegurgitationJACC, 2021
- National Trends and Outcomes in Isolated Tricuspid Valve SurgeryJACC, 2017